ArticleScientific reports2026
TREM1-NLRP3-driven pyroptosis in sepsis-associated acute kidney injury (AKI) with parallel autophagy changes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
- Medicarpin Mediates the Protective Effect of Cell Pyroptosis Against Sepsis-Induced Liver Injury by NLRP3/GSDMD/Caspase-1 Axis.Journal of biochemical and molecular toxicology · 2026Article
- Crosstalk of regulated cell death pathways in sepsis-associated acute kidney injury: implications for therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SAKI) is a leading cause of critical illness and death, yet its upstream drivers remain unclear. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies innate immune signaling. We investigated whether TREM-1 acts upstream of the NLRP3 inflammasome to promote pyroptotic injury in septic kidneys, while documenting accompanying changes in autophagy. Male mice with genetic deletion of Trem1 and wild-type littermates underwent cecal ligation and puncture; kidneys and serum were collected at 24 h. A subset received pharmacologic modulation of the NLRP3 inflammasome (MCC950 inhibitor or nigericin activator). Renal injury was assessed by histology and tubular injury scores, serum creatinine and blood urea nitrogen, and cytokines. Inflammasome and pyroptosis readouts (NLRP3, cleaved caspase-1, cleaved gasdermin D, interleukin-1β) and autophagy markers (LC3B, Beclin-1, Atg5) were measured by Western blot and enzyme-linked immunosorbent assay. In human proximal tubular epithelial cells (HK-2), TREM-1 was overexpressed or silenced and cells were stimulated with lipopolysaccharide; the same readouts were quantified. Trem1 deletion reduced kidney injury after sepsis, with lower tubular injury scores, improved serum creatinine and blood urea nitrogen, and decreased circulating cytokines. Renal inflammasome–pyroptosis activity was blunted in Trem1-deficient mice, with reduced NLRP3, cleaved caspase-1, cleaved gasdermin D, and interleukin-1β. Pharmacologic modulation aligned with this axis: MCC950 lessened injury in wild-type mice, whereas nigericin aggravated injury despite Trem1 deficiency. In tubular cells, TREM-1 overexpression increased NLRP3 activation, interleukin-1β release, and pyroptosis markers, while TREM-1 knockdown produced the opposite pattern. Across models, Trem1 loss or inhibition was associated with higher autophagy markers. Limited to the autophagy non-perturbed experimentally, these increases are interpreted as concomitant rather than causal. TREM-1 functions as an upstream amplifier of NLRP3 inflammasome activation and pyroptotic tubular injury in SAKI. Autophagy marker changes accompanied TREM1 loss; their functional relevance to NLRP3 activation remains to be determined. These data support soluble TREM-1 as a candidate early biomarker and nominate TREM-1 as a therapeutic target. Future work should define time courses, test post-insult TREM-1 blockade, and link circulating or urinary TREM-1 with renal inflammasome signatures to refine risk stratification and guide intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.